etanidazole has been researched along with Glial Cell Tumors in 12 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the toxicity and maximum tolerated dose of etanidazole administered concurrently with hyperfractionated radiation therapy (HRT) for children with brainstem glioma." | 9.10 | A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. ( Barnes, P; Billett, AL; Coleman, CN; Dutton, SC; Goumnerova, L; Kieran, M; Marcus, KJ; Pomeroy, SL; Tarbell, NJ, 2003) |
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 9.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| "To determine the toxicity and maximum tolerated dose of etanidazole administered concurrently with hyperfractionated radiation therapy (HRT) for children with brainstem glioma." | 5.10 | A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. ( Barnes, P; Billett, AL; Coleman, CN; Dutton, SC; Goumnerova, L; Kieran, M; Marcus, KJ; Pomeroy, SL; Tarbell, NJ, 2003) |
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 5.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marotta, D | 1 |
| Karar, J | 1 |
| Jenkins, WT | 7 |
| Kumanova, M | 1 |
| Jenkins, KW | 1 |
| Tobias, JW | 1 |
| Baldwin, D | 1 |
| Hatzigeorgiou, A | 1 |
| Alexiou, P | 1 |
| Evans, SM | 7 |
| Alarcon, R | 1 |
| Maity, A | 1 |
| Koch, C | 1 |
| Koumenis, C | 1 |
| Ziemer, LS | 1 |
| Kachur, AV | 1 |
| Shuman, AL | 1 |
| Cardi, CA | 1 |
| Karp, JS | 1 |
| Alavi, A | 1 |
| Dolbier, WR | 1 |
| Koch, CJ | 6 |
| Marcus, KJ | 1 |
| Dutton, SC | 1 |
| Barnes, P | 1 |
| Coleman, CN | 2 |
| Pomeroy, SL | 1 |
| Goumnerova, L | 1 |
| Billett, AL | 1 |
| Kieran, M | 1 |
| Tarbell, NJ | 1 |
| Judy, KD | 1 |
| Dunphy, I | 1 |
| Hwang, WT | 1 |
| Nelson, PT | 1 |
| Lustig, RA | 1 |
| Jenkins, K | 1 |
| Magarelli, DP | 1 |
| Hahn, SM | 1 |
| Collins, RA | 1 |
| Grady, MS | 1 |
| Vordermark, D | 1 |
| Kumar Naraharisetti, P | 1 |
| Yung Sheng Ong, B | 1 |
| Wei Xie, J | 1 |
| Kam Yiu Lee, T | 1 |
| Wang, CH | 1 |
| Sahinidis, NV | 1 |
| Joiner, B | 2 |
| Laughlin, KM | 1 |
| Lord, EM | 2 |
| Riese, NE | 1 |
| Loeffler, JS | 1 |
| Wen, P | 1 |
| Alexander, E | 1 |
| Black, PM | 1 |
| Shapiro, M | 1 |
| Rasey, JS | 1 |
| Hofstrand, PD | 1 |
| Chin, LK | 1 |
| Tewson, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer[NCT01881451] | 5 participants (Actual) | Observational | 2013-08-31 | Terminated (stopped due to Due to slow accrual and access to the study drug.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for etanidazole and Glial Cell Tumors
| Article | Year |
|---|---|
A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Stem Neoplasms; Child; Child, Preschool | 2003 |
A phase I study of etanidazole and radiotherapy in malignant glioma.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Etanidazole; Female; Glioma; Humans; Male; Middle Aged | 1994 |
10 other studies available for etanidazole and Glial Cell Tumors
| Article | Year |
|---|---|
In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection.
Topics: Animals; Cell Hypoxia; Etanidazole; Gene Expression Profiling; Gene Expression Regulation, Neoplasti | 2011 |
Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Etanidazole; Feasibility Studies; Fluorine Radiois | 2003 |
Hypoxia is important in the biology and aggression of human glial brain tumors.
Topics: Aged; Brain Neoplasms; Electrodes; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypoxia; | 2004 |
Significance of hypoxia in malignant glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84.
Topics: Antineoplastic Agents; Brain Neoplasms; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypo | 2005 |
In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Line, Tumor; Drug Delivery | 2007 |
Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide].
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Hypoxia; Etanidazole; Fluorescence; Gli | 1995 |
2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Hypoxia; Etanidazole; Glioma; Hydrocarb | 1996 |
Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status.
Topics: Animals; Benzimidazoles; Cell Hypoxia; Cell Survival; Etanidazole; Fluorescent Dyes; Glioma; Humans; | 1997 |
Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Cell Hypoxia; Chromatography, High Pressure Liquid; Con | 1999 |
Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
Topics: Animals; Cell Hypoxia; Etanidazole; Glioma; Hydrocarbons, Fluorinated; Indicators and Reagents; Ion- | 2000 |